Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IsoRay brachytherapy seeds

This article was originally published in The Gray Sheet

Executive Summary

IsoRay gains 510(k) clearance for its Proxcelan Cesium-131 brachytherapy seeds preloaded into flexible braided strands and surgical mesh. The Aug. 11 clearance includes indications for lung and head and neck tumors as well as tumors in other organs, according to the company. "The FDA's decision will accelerate our strategy to significantly broaden the scope of Cesium-131 cancer treatments well beyond the current major prostate market," says IsoRay CEO Dwight Babcock
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027819

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel